Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Vitamin K3H2. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 3/20 | 0.81 |
| ▸ | LMNA | P02545 | 1/20 | 0.81 |
| ▸ | MAPT | P10636 | 5/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.59 |
| ▸ | MCL1 | Q07820 | 3/20 | 0.59 |
| ▸ | MEN1 | O00255 | 2/20 | 0.59 |
| ▸ | POLB | P06746 | 2/20 | 0.59 |
| ▸ | NSD2 | O96028 | 1/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.57 |
| ▸ | GAA | P10253 | 2/20 | 0.57 |
| ▸ | TP53 | P04637 | 1/20 | 0.57 |
| ▸ | THRB | P10828 | 1/20 | 0.56 |
| ▸ | PKM | P14618 | 2/20 | 0.53 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.44 |
| ▸ | GALK1 | P51570 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Vitamin K3H2 SCHEMBL515420 | 1.00 | HTT (0.81) | HTTLMNAMAPTKDM4EKMT2A | |
| Vitamin K3H2 SCHEMBL297164 | 0.90 | HTT (1.00) | HTTLMNAMAPTKDM4EKMT2A | |
| Vitamin K3H2 SCHEMBL29525544 | 0.90 | HTT (1.00) | HTTLMNAMAPTKDM4EKMT2A | |
| Vitamin K3H2 SCHEMBL2887680 | 0.88 | HTT (0.95) | HTTLMNAMAPTKDM4EKMT2A | |
| Vitamin K3H2 SCHEMBL516200 | 0.85 | HTT (0.81) | HTTLMNAMAPTKDM4EKMT2A | |
| Vitamin K3H2 SCHEMBL515182 | 0.85 | HTT (0.81) | HTTLMNAMAPTKDM4EKMT2A | |
| Vitamin K3H2 SCHEMBL28664356 | 0.85 | HTT (0.81) | HTTLMNAMAPTKDM4EKMT2A | |
| Vitamin K3H2 SCHEMBL28687103 | 0.84 | HTT (0.68) | HTTLMNAMAPTKDM4EKMT2A | |
| Vitamin K3H2 SCHEMBL515298 | 0.84 | HTT (0.68) | HTTLMNAMAPTKDM4EKMT2A | |
| Vitamin K3H2 SCHEMBL21437091 | 0.84 | HTT (0.72) | HTTLMNAMAPTKDM4EKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112778114-B | Efficient and environment-friendly method for synthesizing vitamin K1 | 杭州浙中医药科技有限公司 | 2025-05-30 | — | — | CN | claimed |
| CN-112778114-A | Efficient and environment-friendly method for synthesizing vitamin K1 | 杭州浙中医药科技有限公司 | 2021-05-11 | — | — | CN | claimed |
| CN-111380966-A | Method for determining related substances of vitamin K1 bulk drug | 南京艾德凯腾生物医药有限责任公司 | 2020-07-07 | — | — | CN | claimed |
| CN-104857515-B | Drug core composition for controlled release drug delivery and osmotic pump preparation containing the same | 中国科学院上海药物研究所 | 2020-01-10 | — | — | CN | claimed |
| CN-112778114-B | Efficient and environment-friendly method for synthesizing vitamin K1 | 杭州浙中医药科技有限公司 | 2025-05-30 | — | — | CN | disclosed |
| CN-112778114-B | Efficient and environment-friendly method for synthesizing vitamin K1 | 杭州浙中医药科技有限公司 | 2025-05-30 | — | — | CN | disclosed |
| CN-113855754-B | Traditional Chinese medicine composition for removing blood stasis and stopping bleeding as well as preparation method and application thereof | 北京盛世良方医药科技有限公司 | 2024-07-12 | — | — | CN | disclosed |
| CN-114128794-B | Feed for termite animals, preparation method thereof and method for raising termite animals by feed | 广东长隆集团有限公司 | 2024-03-26 | — | — | CN | disclosed |
| CN-114128794-A | Feed for feeding young ant, preparation method thereof and method for feeding young ant by using feed | 广东长隆集团有限公司 | 2022-03-04 | — | — | CN | disclosed |
| CN-113855754-A | Traditional Chinese medicine composition for removing blood stasis and stopping bleeding as well as preparation method and application thereof | 北京盛世良方医药科技有限公司 | 2021-12-31 | — | — | CN | disclosed |
| CN-112778114-A | Efficient and environment-friendly method for synthesizing vitamin K1 | 杭州浙中医药科技有限公司 | 2021-05-11 | — | — | CN | disclosed |
| CN-112778114-A | Efficient and environment-friendly method for synthesizing vitamin K1 | 杭州浙中医药科技有限公司 | 2021-05-11 | — | — | CN | disclosed |
| CN-102503818-B | Method for synthesizing menadiol acetate | ANHUI WANHE PHARMACEUTICAL CO LTD | 2015-01-07 | — | — | CN | disclosed |
| CN-102503818-A | Method for synthesizing menadiol acetate | ANHUI WANHE PHARMACEUTICAL CO LTD | 2012-06-20 | — | — | CN | disclosed |
| CN-102503818-A | Method for synthesizing menadiol acetate | ANHUI WANHE PHARMACEUTICAL CO LTD | 2012-06-20 | — | — | CN | disclosed |
| US-7439402-B2 | Method for producing quinone compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2008-10-21 | — | — | US | disclosed |
| US-20070060761-A1 | Method for producing quinone compound | EISAI CO., LTD. | 2007-03-15 | — | — | US | disclosed |
| EP-0592962-B1 | Purification method of crude product | EISAI KAGAKU KK (JP) | 1997-07-16 | — | — | EP | disclosed |
| US-5547580-A | CHROMATOGRAPHY ON A SILICA GEL SOLID SUPPORT USING METHANOL, HEXANE MIXTURE | EISAI CHEMICAL CO., LTD. (JP) | 1996-08-20 | — | — | US | disclosed |
| EP-0592962-A1 | Purification method of crude product | EISAI CHEMICAL CO., LTD. (JP) | 1994-04-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070060761-A1 | Method for producing quinone compound | SDHA, SQOR, SDHB | HTT 2229/4885LMNA 2914/4885MAPT 1598/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.